A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Erythromycin (ERY-TAB)

Macrolide class · 15 generic manufacturers · 34 ANDAs filed at FDA.

First FDA approval1994-07-29
Generic availableYes · 15 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.355/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.19
Across all dosage forms in distribution.
Highest NADAC
$1.80
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Erythromycin used for?

Erythromycin is a Macrolide medication tracked in Medicare Part D.

Is there a generic for Erythromycin?

Yes. 34 ANDAs filed at FDA, 15 generic manufacturers currently shipping.

How much does my plan pay for Erythromycin?

Across 329 Part D plans, Erythromycin averages $1.19/unit (NADAC). Lowest available: $0.355/unit. Highest in distribution: $1.80/unit.

Is Erythromycin on the FDA shortage list?

No. Erythromycin is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Macrolide3 alternatives in D1
01
Erythromycin Ethylsuccinate
Brand: E.E.S
$0.822Lowest NADAC
4Generic mfrs
$5.3MCY24 Part D spend
Compare →
02
Erythromycin Topical Solution
Macrolide
$0.355Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Erythromycin and Benzoyl Peroxide
Brand: Benzamycin
$0.974Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.